v3.25.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Operating Financial Segment

The following table provides the non-GAAP operating financial results of the Bioelectronic Innovations segment:

   2025   2024 
   Three months ended March 31, 
   2025   2024 
Net sales *  $6,719   $5,443 
Cost of goods sold   1,013    888 
Gross profit   5,706    4,555 
Operating expenses          
Research and development   642    399 
General and administrative   4,333    3,884 
Sales and marketing   4,553    4,121 
Total operating expenses   9,528    8,404 
Loss from operations   (3,822)   (3,849)
Other (income) expense          
Interest and other income   (83)   (225)
Other expense   164    4 
Total other (income) expense   81    (221)
Loss before income taxes   (3,903)   (3,628)
Benefit from income taxes   48    122 
Net loss  $(3,855)  $(3,506)

 

*See Note 4 Revenue for geographical and disaggregation information.